Denis Corin, CEO of Q BioMed Inc. (OTCQB: QBIO), called in to SmallCapvoice.com to go over his company’s business model, the markets they serve, their products and formulations including QBM-001, in support of Q BioMed’s Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children, and Metastron.
Q BioMed Inc., ‘Q’, is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need. Please visit http://www.qbiomed.com and sign up to receive regular updates. Follow us on social media @QBioMed.
This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.